newsfilter
← Earnings
Earnings Releases·

Faeth Therapeutics — Third Quarter 2026 Earnings Summary

  • Cash and marketable securities surged to $174.8 million as of September 30, 2026, from $21.2 million at year-end 2025, while total operating expenses rose to $22.1 million from $4.9 million in the prior year period.
  • Net loss widened to $20.4 million ($0.79 per share) for the quarter, compared to $4.6 million ($3.62 per share) in Q3 2025, driven by increased R&D and G&A expenses alongside a significant increase in weighted-average shares outstanding to 25.8 million.
  • The FDA granted Fast Track designation for PIKTOR plus paclitaxel in endometrial cancer, with topline Phase 2 PIK-201 data expected by year-end 2026 and initial PIK-101 breast cancer data anticipated in 2027.
  • Management highlighted PK/PD analysis supporting the Phase 2 dose selection for PIKTOR, a multi-node inhibitor targeting the PAM pathway dysregulated in up to 50% of solid tumors, while noting risks related to clinical trial execution and future financing needs.
Company
FAETH THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology